Abstract
De novo drug discovery involves high financial expenditure, poor success rates, and extended trial periods in today’s world. Through reassessing biological objectives and action mechanisms for licensed medications, drug repositioning offers a viable solution to these problems. When high-throughput techniques are combined with genome-wide screenings, network study, genome-wide metabolic modeling, and machine learning-based approaches, novel drug–target signatures can be proposed, in addition to previously unknown mechanisms of action for existing medications. This chapter explores current medication repositioning difficulties using maintained high-performance multi-omics datasets and genome-based scanning methods, and, most importantly, their implementation in systems biology/medicine.
Publisher
Royal Society of Chemistry